<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03577795</url>
  </required_header>
  <id_info>
    <org_study_id>D5980R00005</org_study_id>
    <nct_id>NCT03577795</nct_id>
  </id_info>
  <brief_title>A Prospective Cohort Study of Asthma and COPD Overlap in Japanese COPD Patients Using the Diagnostic Criteria of The Japanese Respiratory Society</brief_title>
  <acronym>ACO-Registry</acronym>
  <official_title>A Prospective Cohort Study of Asthma and COPD Overlap in Japanese COPD Patients Using the Diagnostic Criteria of The Japanese Respiratory Society</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Linical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a multicentered and non-interventional prospective cohort study. Study centers&#xD;
      shall be the institutions where the examinations, adopted in the ACO diagnostic criteria9)&#xD;
      from The Japanese Respiratory Society, are performed at least once a year as a part of their&#xD;
      regular practice. Physicians participating in the study will consecutively register by means&#xD;
      of central registration outpatients who have the characteristics of COPD in the ACO&#xD;
      diagnostic criteria9) from The Japanese Respiratory Society, and who have been confirmed to&#xD;
      satisfy the inclusion criteria whereas not violating the exclusion criteria.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a multicentered and non-interventional prospective cohort study. Study centers&#xD;
      shall be the institutions where the examinations, adopted in the ACO diagnostic criteria9)&#xD;
      from The Japanese Respiratory Society, are performed at least once a year as a part of their&#xD;
      regular practice. Physicians participating in the study will consecutively register by means&#xD;
      of central registration outpatients who have the characteristics of COPD in the ACO&#xD;
      diagnostic criteria9) from The Japanese Respiratory Society, and who have been confirmed to&#xD;
      satisfy the inclusion criteria whereas not violating the exclusion criteria. The physicians&#xD;
      will collect data including the patients' results from medical examinations by using the ACO&#xD;
      diagnostic criteria, at each time point (on the registration, after 1 year, and after 2&#xD;
      years). Electronic case report forms completed by participating physicians and questionnaires&#xD;
      completed by patients will be used to collect data.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 19, 2018</start_date>
  <completion_date type="Actual">February 19, 2021</completion_date>
  <primary_completion_date type="Actual">February 19, 2021</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>2 Years</target_duration>
  <primary_outcome>
    <measure>Prevalance of ACO</measure>
    <time_frame>2 years</time_frame>
    <description>Proportion of patients diagnosed with ACO at least once at the time of registration, 1 year later, and 2 years later among all registered patients&#xD;
The number and proportion of ACO patients and non-ACO patients at the time of registration among patients who have data required for the diagnosis of ACO at the time of registration</description>
  </primary_outcome>
  <enrollment type="Actual">710</enrollment>
  <condition>Pulmonary Disease, Chronic Obstructive</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Outpatients should be 40 years old or older who satisfy the characteristics of COPD from&#xD;
        The Japanese Respiratory Society's ACO diagnostic criteria within the past years or on the&#xD;
        registration as well as who can regularly visit their study center in Japan.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients from whom written consent to participate in this study has been obtained&#xD;
&#xD;
          2. Patients ≥40 years old&#xD;
&#xD;
          3. Patients with FEV1/FVC ratio &lt;70% after bronchodilator inhalation within the past year&#xD;
             or on the registrationa&#xD;
&#xD;
          4. Patients who satisfy any one of the following items:&#xD;
&#xD;
        1) Smoking history (≥10 pack-years) or comparable air pollution exposure on the&#xD;
        registrationa 2) Presence of the low attenuation area on chest CT demonstrating&#xD;
        emphysematous alteration within the past year or on the registration a,b, 3) Impaired&#xD;
        pulmonary diffusing capacity (%DLCO &lt;80% or %DLCO/VA &lt;80%) within the past year or on the&#xD;
        registrationa 4) Patients deemed capable of visiting their study center in Japan at least&#xD;
        once a year on an outpatient basis&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients who participated in other interventional studies such as clinical trial&#xD;
             within the last 8 weeks.&#xD;
&#xD;
          2. Patients who are unsuitable for their enrollment in this study, judged by the&#xD;
             participating physician, because they cannot comply with the procedures, restrictions,&#xD;
             and requirements of this study (e.g., patients with dementia).&#xD;
&#xD;
          3. Patients with exacerbationsa of COPD or asthma within the last 8 weeks. a COPD&#xD;
             exacerbation: State of increased shortness of breathing, increased cough and sputum,&#xD;
             and occurrence or exacerbation of chest discomfort that requires a change of treatment&#xD;
             during the stable phase. However, exacerbation preceded by other disorders (e.g.,&#xD;
             heart failure, pneumothorax, pulmonary thromboembolism) is excluded.&#xD;
&#xD;
             Asthma exacerbation: Occurrence of paroxysmal/variable cough/sputum/wheezing/dyspnea&#xD;
             caused by various factors including respiratory infection.&#xD;
&#xD;
          4. Patients carrying following disorders that should be distinguished from COPD or&#xD;
             asthma:&#xD;
&#xD;
        Diffuse panbronchiolitis, congenital sinobronchial syndrome, occlusive panbronchiolitis,&#xD;
        bronchiectasis, pulmonary tuberculosis, pneumoconiosis, lymphangioleiomyomatosis,&#xD;
        congestive heart failure, interstitial lung disease, lung cancer, laryngitis, epiglottitis,&#xD;
        vocal cord dysfunction, intratracheal tumor, airway foreign substance, tracheomalacia,&#xD;
        bronchial tuberculosis, pulmonary thromboembolism, cough induced by drug such as&#xD;
        angiotensin-converting enzyme inhibitor, spontaneous pneumothorax, hyperventilation&#xD;
        syndrome, psychogenic cough&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Masakazu Ichinose, Professor</last_name>
    <role>Study Chair</role>
    <affiliation>Tohoku University School of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Tohoku University School of Medicine</name>
      <address>
        <city>Sendai</city>
        <state>Miyagi</state>
        <zip>9808574</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>May 23, 2018</study_first_submitted>
  <study_first_submitted_qc>June 22, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 5, 2018</study_first_posted>
  <last_update_submitted>April 23, 2021</last_update_submitted>
  <last_update_submitted_qc>April 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>COPD, ACO, RWE</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

